Naperville, IL -- (SBWire) -- 03/20/2015 --Reportstack, provider of premium market research reports announces the addition of Ibodutant (Irritable Bowel Syndrome) - Forecast and Market Analysis to 2023 market report to its offering

Ibodutant (Irritable Bowel Syndrome) - Forecast and Market Analysis to 2023

Summary

Irritable Bowel Syndrome (IBS) is a common disorder characterized by abdominal discomfort associated with altered bowel function. Although IBS is not a life-threatening disorder, it has a considerable effect on patients quality of life (QOL). In terms of volume, the IBS market is a large, albeit nave, one, with only a small number of pharmacotherapies indicated for the treatment of the disorder, and it is also characterized by significant unmet needs.

Ibodutant is being developed by Menarini for the treatment of women with IBS-D. The Phase III program for ibodutant was initiated in Q1 2014 with two Phase III clinical trials, a 12-week study and a 52-week study, both of which were designed to evaluate the efficacy and safety of this product (Menarini, NCT02107196; Menarini, NCT02120027).

Scope

- Overview of IBS, including epidemiology, etiology, symptoms, diagnosis, pathology and treatment guidelines as well as an overview on the competitive landscape.

- Detailed information on Ibodutant including product description, safety and efficacy profiles as well as a SWOT analysis.

- Sales forecast for Ibodutant for the top 7 countries from 2013 to 2023.

- Sales information covered for the US, France, Germany, Italy, Spain, UK and Japan.

Reasons to buy

- Understand and capitalize by identifying products that are most likely to ensure a robust return.

- Stay ahead of the competition by understanding the changing competitive landscape for IBS.

- Effectively plan your M&A and partnership strategies by identifying drugs with the most promising sales potential.

- Make more informed business decisions from insightful and in-depth analysis of Ibodutant performance.

- Obtain sales forecast for Ibodutant from 2013-2023 in top 7 countries (the US, France, Germany, Italy, Spain, UK and Japan).

Complete report is available
http://www.reportstack.com/product/194759/ibodutant-irritable-bowel-syndrome-forecast-and-market-analysis-to-2023.html

Contact:
Roger Campbell
roger@reportstack.com
Naperville
Illinois
United States
Ph: 888-789-6604